期刊文献+

艰难梭菌A毒素受体结合区基因在乳链菌中的表达 被引量:2

Expression of Clostridium difficile toxin A receptor binding domain in Lactococcus lactis
下载PDF
导出
摘要 目的:在乳链菌内表达艰难梭菌A毒素受体结合区并检测其活性.方法:提取艰难梭菌标准株基因组DNA,扩增编码艰难梭菌毒素A毒素受体结合区的羧基未端基因重复序列(14CDTA),分别连接到乳链菌表达载体pNBC1000及pNBC2000,转化乳链菌,蛋白电泳及Western-blot检测蛋白定位表达情况.结果:成功构建了14CDTA乳链菌表达载体,并在乳链菌内表达了艰难梭菌受体结合区蛋白,分泌表达的艰难梭菌受体结合区蛋白大小约39.2 ku,膜锚定表达的受体结合区蛋白大小约为55.1 ku,所表达的蛋白均可与艰难梭菌A毒素多克隆抗体发生免疫印迹反应.结论:表达艰难梭菌受体结合区蛋白的重组乳链菌可以识别艰难梭菌A毒素多克隆抗体,为研制防治艰难梭菌疫苗的口服生态活菌亚单位疫苗奠定了一定基础. AIM: To expreess the Clostridium difficile toxin A receptor binding domain and test its bioactivity. METHODS: The gene of fourteen of the 38 C-terminal toxin A repeats (14CDTA) coding for the clostridium difficile toxin A receptor binding domain was amplified and then cloned into the lactococcus lactis expression system pNBC1000 and pNBC2000 to form pNBC1001 and pNBC2001, the confirmed sequence was cut and ligated to pTRKH2 a shuttle vector for E. coli and Lactococcus lactis to generate pNBCL1001 and pNBCL2001, pNBCL1001 and pNBCL2001 were transformed into Lactococcus lactis by electroporation. Protein electrophoresis and Western-Blot were used to detect the expession of 14CDTA and its bioactivity. RESULTS: The 14CDTA expression vectors were constructed successfully. The secretory form of 14CDTA had a weight of 39.2 ku and the cell anchored form of 14CDTA had a weight of 55.1 ku. All the forms of 14CDTA could be deteced with the clostridium difficile toxin A multicloned antibody by Western Blotting. CONCLUSION: The recombinant lactococcus lactis expressing the 14CDTA may lay a foundation for vaccine against Clostridium difficile.
出处 《第四军医大学学报》 北大核心 2009年第18期1676-1680,共5页 Journal of the Fourth Military Medical University
基金 国家自然科学基金自由申请面上项目(30570839) 广东省自然科学基金(05004735)
关键词 艰难梭菌 A毒素 受体结合区 乳链菌 clostridium difficile toxin A receptor binding domain Lactococcus lactis
  • 相关文献

参考文献25

  • 1王薇.难辨梭菌性肠炎[J].国外医学(消化系疾病分册),2003,23(2):96-99. 被引量:12
  • 2刘杨,王明贵.艰难梭菌相关性腹泻研究进展[J].中国感染与化疗杂志,2006,6(4):280-283. 被引量:5
  • 3Baierlein SA, Wistop A. Clostridium difficile [ J ]. N Engl J Med,2009, 360(6) :636 -637.
  • 4Bouza E. Clostridium difficile infection: same incidence and worse prognosis[J]. Clin Infect Dis, 2009, 48 (5) :577 - 579.
  • 5杨清明 于世军 刘慧峰.多重耐药的难辨梭状芽胞杆菌引起医院感染1例报告.中华医院感染学杂志,2001,11(2):151-152.
  • 6Huang H, Wu S, Wang M, et al. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes[J]. Int J Antimicrob Agents, 2009, 33(4) : 339 -342.
  • 7Pepin J. Vancomycin for the treatment of clostridium difficile Infection: for whom is this expensive bullet really magic[ J]. Clin Infect Dis, 2008, 46(10) :1493 - 1498.
  • 8Chatel JM, Nouaille S, Ariel-Patient K, et al, Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta- lactoglobulin and evaluation of its immunogenicity in mice[J].Appl Environ Microbiol, 2003, 69 ( 11 ) :6620 - 6627.
  • 9Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 [ J ]. Science, 2000, 289 (8) :1352 -1355.
  • 10Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interlenkin 10 [ J ]. Nat Biotechnol, 2003, 21 C 7 ) : 785 - 789.

二级参考文献43

  • 1Pituch H,Van. den Braak N,Van Belkum W,et al. Copyright by the Eropean Society of Clinical Microbiology and Infectious Diseases, 2001 ;7(6) :442--446.
  • 2Bouza E,Pelaez T,Alonso R, et al. Journal of Hospital Infection, 2001 ;48(3) :233--237.
  • 3Michelh JA,Amin K,David L, et al. Journal of Microbiology,2000;38(7) :2706--2714.
  • 4Olson MM, Shanholtzer CJ, Lee JT, et al. Infect Contr Hosp Epidemiol, 1994; 15 ( 3 ) : 371 -- 381.
  • 5Don O'C,Pearl H,Martin C,et al. Journal of Clinical Microbiology,2001 ;39(8) :2846--2849.
  • 6Shetler R,Nieuwenhuis,SM Wreh,et al. Surg Endosc,2001;1S(S):6S3-6S9.
  • 7Said FY,Tonia M,Young F, et al. Mayo Clin Proc, 2001;76(7) :725--730.
  • 8Lorraine K,Richard JF,Ciaran PK, et al. Clinical of North American ,2001 ;9(30) :753--777.
  • 9Hend H,Issam R,Virgina G, et al. Infection Control and Hospital Epidemiology, 2000;21(3) :226--228.
  • 10Matthew RT, Scott CL, Douglas R, et al. Mayo Clin Proc,2001 ;76(9) :883--889.

共引文献20

同被引文献77

  • 1杨晓强,彭春秀,姜泊,邢锐,张绍荣,陈学清.乳链菌表达系统的构建及其鉴定[J].第一军医大学学报,2005,25(10):1232-1235. 被引量:5
  • 2徐波,曹郁生,陈燕,郭兴华.乳酸乳球菌食品级诱导表达系统的构建及异源蛋白的表达[J].微生物学报,2007,47(4):604-609. 被引量:17
  • 3TREGONING J S, NIXON P, KURODA H, et al. Expression of tetanus toxin Fragment C in tobacco chlorop lasts [ J ]. Nucleic Acids Res, 2003, 31(4) : 1174 -1179.
  • 4MANNAM P, JONES K F, GELLER B L. Mncosal vaccine made from live, recombinant Lactococcus laetis protects mice against pharyngeal infection with Streptococcus pyogenes [ J ]. Infect Im- mun, 2004, 72(6) : 3444 -3450.
  • 5GAHAN M E, WEBSTER D E, WESSELINGH S L, et al. Bacte- rial antigen expression is an important component in inducing an immune response to orally administered Salmonella - delivered DNA vaccines[J]. PLoS One, 2009, 4(6) : e6062.
  • 6RADKEVICH BROWN O, PIECHOCKI M P, BACK J B, et al. Intratumoral DNA electroporation induces anti - tumor immunity and tumor regression [ J ]. Cancer Immunol Immunother, 2010, 59 (3) : 409 -417.
  • 7IURESCIA S, FIORETTI D, PIERIMARCHI P, et al. Genetic immunization with CDR3 - based fusion vaccine confers protection and long - term tumor - free survival in a mouse model of lympho- ma[J]. J Biomed Biotechnol, 2010, 2010: 316069.
  • 8GU Q, SONG D, ZHU M. Oral vaccination of mice against Heli- cobacter pylori with recombinant Lactococcus lactis expressing ure- ase subunit B[J]. FEMS Immunol Med Microbiol, 2009, 56(3) : 197 - 203.
  • 9MIFUNE J, GRAGE K, REHM B H. Production of functionalized biopolyester granules by recombinant Lactococcus lactis [ J ]. Appl Environ Microbiol, 2009, 75( 14): 4668-4675.
  • 10BAHEY EL DIN M, CASEY P G, GRIFFIN B T, et al. Lactococ- cus lactis - expressing listeriolysin O ( LLO ) provides protection and specific CD8 ( + ) T cells against Listeria monocytogenes in the murine infection model[ J]. Vaccine, 2008, 26(41 ) : 5304 - 5314.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部